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Background
Disruption to VLDL metabolism and removal of beta
amyloid protein from neurons seems to play a pivotal
role in the development of late- onset disease Alzhei-
mer’s disease (AD). Surveys suggest the apolipoprotein
E4 allele is present in between 45-60% of late-onset AD
and, together with the SORL-1 gene, involved in the reg-
ulation of amyloid precursor protein (APP), probably
accounts for a majority of late onset AD. Although the
link of ApoE4 allele to AD is well documented, as yet
there is no clinical consensus on whether genotyping
has any value. Only ~ 30% of individuals with the Apo
E4 allele will develop AD as co-related environmental
factors, such as hypertension, cigarette smoking and
dyslipidemia, are important contributors to outcome, in
addition to epigenetic and epistaxis mechanisms yet to
determined. This might suggest that individuals carrying
the allele and identified to be ‘at risk’ might benefit
from early intervention programs. Two studies pub-
lished on the effect of statin therapy in AD prevention
have shown no effect, though these studies might have
been underpowered [1,2].
Case reports
Individuals with the ApoE4 allele consistently demon-
strate thickened cIMT (Carotid Intima Media Thick-
ness) readings in the absence of co-morbidity factors
and clinical disease. We report on observational data in
10 patients who possess the ApoE4 allele demonstrating
improved cIMT measurement when treated with statin
therapy and lifestyle modification, despite otherwise nor-
mal lipid levels and co-morbidity factors. cIMT is a sur-
rogate marker for atherosclerotic load and predictor for
future cardiovascular events. Improvements in cIMT
imply a reduction in future atherosclerotic events.
Conclusion
Observational data in a smalln u m b e ro fp a t i e n t ss u g -
gests a marked benefit from statin therapy in individuals
possessing the ApoE4 allele. ApoE4 is a risk factor for
cardiovascular disease (CVD) as well as AD and statin
therapy might have a role early in the pathogenesis of
cardiovascular disease even where lipid levels are normal
or low. Furthermore, as atherosclerosis is a co-morbidity
factor in AD, it also implies that early statin therapy
might delay the onset of AD.
Published: 11 October 2010
References
1. Shepherd J, Blauw GJ, Murphy MB, et al: Pravastatin in elderly individuals
at risk of vascular disease (PROSPER): a randomized controlled trial.
Lancet. 2002, 360:1623-1630.
2. McGuinness B, et al: Statins for the treatment of Alzheimer’s disease and
dementia. Cochrane Database Syst Rev 2009.
doi:10.1186/gb-2010-11-S1-P33
Cite this article as: Richards: A role for statin therapy in Alzheimer’s
disease. Genome Biology 2010 11(Suppl 1):P33.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Department of Medicine, Bond University, Gold Coast, Queensland, Australia
Richards Genome Biology 2010, 11(Suppl 1):P33
http://genomebiology.com/2010/11/S1/P33
© 2010 Richards; licensee BioMed Central Ltd.